Clinical trials
Glioma, Malignant clinical trials
Below are recruiting glioma, malignant clinical trials, each written for real people, not researchers. We’re tracking 76 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07468136RecruitingPhase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas
This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.
Rochester, MinnesotaAges 18 years+ - NCT06942104RecruitingPhase 1
New imaging agent for advanced solid tumors
This trial tests a new imaging agent (18F-TRX) to see if it can better detect cancer spread in people with advanced solid tumors. It is designed for patients with specific cancers like high-grade brain tumors, advanced kidney cancer, or prostate cancer that has stopped responding to hormone therapy.
San Francisco, CaliforniaAges 18 years+ - NCT06160492RecruitingPhase 3
Testing a Glowing Dye to Improve Brain Tumor Removal
This trial compares two surgical techniques for removing malignant brain tumors: one using a special dye (5-ALA) that makes tumor cells glow under a blue light, versus the standard white light surgery. The goal is to see if the dye-guided approach helps surgeons remove more of the tumor safely.
Guangzhou, GuangdongAges 18–70 - NCT04945148RecruitingPhase 2
Metformin plus radiation and chemo for glioblastoma subtype
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
Suresnes, Hauts de SeineAges 18 years+ - NCT05226494RecruitingPhase 1
Test drug fb-PMT in recurrent brain cancer patients
This Phase 1 study tests how safe and tolerable fb-PMT is for people with glioblastoma that has come back. It also helps doctors learn the best way to give it and what side effects to watch for.
New Haven, ConnecticutAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+ - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT06470711Recruiting
Mapping brain electrical properties with MRI
This study uses MRI scans to map the brain's electrical properties in healthy volunteers and in people who have had surgery for a brain tumor (glioma). It aims to better understand brain function and tumor effects.
Scottsdale, ArizonaAges 18 years+ - NCT06917885RecruitingPhase 1
CUE-102 for Recurrent Glioblastoma: A Safety Study
This study tests an experimental drug, CUE-102, for people with recurrent glioblastoma. It aims to see if the drug is safe and how well it works. You may be eligible if your tumor has come back once, you have a specific genetic marker (HLA-A*0201), and you are not on other treatments.
Boston, MassachusettsAges 18 years+ - NCT04908709Recruiting
MRI-guided proton therapy for high-grade brain tumors in children
This study looks at how metabolism in a child’s brain tumor changes during proton therapy, using special MRI scans. It may help doctors better understand treatment response and tailor care for pediatric high-grade gliomas.
Atlanta, GeorgiaAges Up to 21 years - NCT05622409Recruiting
Tissue and genetic data registry for diffuse glioma in adults
This study collects tumor tissue and basic medical information to better understand the genes involved in adult diffuse glioma. It may help future treatments by building a detailed research database and matching patients to study arms.
Kaohsiung CityAges 20 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT06914479RecruitingPhase 1
Gene therapy and valacyclovir for recurrent brain tumors in young people
This trial tests a new gene therapy that uses two special viruses and an oral antiviral drug (valacyclovir) to treat brain tumors that have come back in children and young adults. The therapy is given right after surgery to remove the tumor, with the goal of helping your immune system fight the cancer.
Ann Arbor, MichiganAges 3–39 - NCT05976490Recruiting
Support program for people newly diagnosed with brain cancer
This study tests a “NeuroPathways” support intervention for adults who are within 6 weeks of being diagnosed with a malignant (cancerous) brain tumor. It may help patients cope and navigate care during the early, stressful period after diagnosis.
Boston, MassachusettsAges 18 years+ - NCT06099743Recruiting
ASCENT Support Program for Brain Tumor Patients
This trial tests a support program called ASCENT for people recently diagnosed with a malignant brain tumor. It aims to help patients and their families adjust and manage challenges soon after diagnosis.
Boston, MassachusettsAges 18 years+ - NCT07198256Recruiting
AI-assisted diagnosis of brain tumors
This trial tests an AI tool that helps diagnose brain tumors like glioma, brain metastases, and lymphoma using MRI scans. It may allow faster and more accurate diagnosis without needing additional tests.
Hangzhou, ZhejiangAges 18–100 - NCT06624371RecruitingPhase 1
Atovaquone with radiation for children with brain tumors
This trial tests adding atovaquone to standard radiation therapy for children with aggressive brain tumors like high-grade glioma (a fast-growing brain cancer) or medulloblastoma. The goal is to see if this drug, which targets energy production in cancer cells, can make radiation work better.
Atlanta, GeorgiaAges 2–25 - NCT05929495RecruitingPhase 2
Metformin added to standard treatment for newly diagnosed glioblastoma
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
MilanAges 18 years+ - NCT01772771Recruiting
Molecular testing to guide personalized cancer treatment plans
This trial uses special lab tests to look for tumor “molecular fingerprints” in your tumor or blood sample. The goal is to help your care team choose more personalized treatment options based on those results.
Houston, TexasAges Any age - NCT01638130Recruiting
Study of support needs in high-grade brain tumor patients
This study asks people with a high-grade brain tumor and their caregivers about their experiences and support needs. It may help researchers understand what patients and families need during and after chemotherapy.
Leuven, Vlaams-BrabantAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Birmingham, AlabamaAges 16 years+ - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT02800486RecruitingPhase 2
Targeted antibody plus repeat radiation for recurrent brain tumors
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
New York, New YorkAges 18 years+
Hear when a new Glioma, Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioma, malignant?
- Yes. Clin2 currently lists 76 recruiting glioma, malignant studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma, malignant trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma, malignant trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.